Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

Post-Transplant Relapse in Patients Transplanted with Active Acute Myeloid Leukemia (AML) - Treatment Options and Outcomes at a Large AML Referral Center

Julian Ronnacker, Marc-Andre Urbahn, Christian Reicherts, Lina Kolloch, Philipp Berning, Simon Call, Matthias Floeth, Julia Marx, Jan-Henrik Mikesch, Christoph Schliemann, Georg Lenz, Matthias Stelljes

Blood (2024) 144 (Supplement 1): 2177.

https://doi.org/10.1182/blood-2024-203502

Published: 2024

Journal Articles

Potent Activity of Duocarmyin- and Mmaf-Conjugated FLT3-Directed Antibody-Drug Conjugates Towards Acute Myeloid Leukemia Stem Cells in Vitro and In Vivo

Blood (2024) 144 (Supplement 1): 1392.

https://doi.org/10.1182/blood-2024-206832

Published: 2024

Journal Articles

Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling

Blood (2024) 144 (Supplement 1): 853.

https://doi.org/10.1182/blood-2024-201644

Published: 2024

Journal Articles

Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial

Steven Le Gouill, Virginie de Wilde, Toby A. Eyre, Mary B. Callanan, Gandhi Damaj, Alexis Claudel, Adrien Chauchet, Roch Houot, Ronan Le Calloch, Victoria Cacheux, Marc André, Franck Morschhauser, Barbara Burroni, David John Lewis, Benoit Tessoulin, Aurore Touzart

Blood (2024) 144 (Supplement 1): 745.

https://doi.org/10.1182/blood-2024-194357

Published: 2024

Journal Articles

Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa

Blood (2024) 144 (Supplement 1): 575.

https://doi.org/10.1182/blood-2024-202446

Published: 2024

Journal Articles

Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma

Jan Boegeholz, Cedric Rossi, Jordan S Goldstein, Stefan K. Alig, Andrea Garofalo, Mohammad Shahrokh Esfahani, Joseph G. Schroers-Martin, Chih Long Liu, Mari Olsen, Xiaoman Kang, Feng Tian, David Kurtz, Marc Andre, Luc-Matthieu Fornecker, Olivier Casasnovas, Maximilian Diehn, Herve Ghesquieres, Ash A. Alizadeh

Blood (2024) 144 (Supplement 1): 565.

https://doi.org/10.1182/blood-2024-201877

Published: 2024

Journal Articles

COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy

Blood (2024) 144 (Supplement 1): 286.

https://doi.org/10.1182/blood-2024-211949

Published: 2024

Journal Articles

The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients

Blood (2024) 143 (11): 983–995.

https://doi.org/10.1182/blood.2023021564

Published: 2024

Includes: Supplemental data

Journal Articles

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

Michael Wang, Wojciech Jurczak, Marek Trněný, David Belada, Tomasz Wrobel, Nilanjan Ghosh, Mary-Margaret Keating, Tom van Meerten, Ruben Fernandez Alvarez, Gottfried von Keudell, Catherine Thieblemont, Frederic Peyrade, Marc Andre, Marc Hoffmann, Edith Szafer Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam

Blood (2023) 142 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2023-191921

Published: 2023

Journal Articles

Induction and Maintenance Therapy in Elderly Patients with Mantle Cell Lymphoma: Double-Randomized MCL R2 Elderly Clinical Trial By the European Mantle Cell Lymphoma Network

Blood (2023) 142 (Supplement 1): 979.

https://doi.org/10.1182/blood-2023-188788

Published: 2023

Journal Articles

R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

Blood (2023) 142 (Supplement 1): 435.

https://doi.org/10.1182/blood-2023-172951

Published: 2023

Journal Articles

Results of the Phase II of Epirchop Study, Evaluating the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): A Lysa Study

Clementine Sarkozy, Thierry Jo Molina, Roch Houot, Sydney Dubois, Gian Matteo Pica, Philippe Ruminy, Charles Herbaux, Thomas Gastinne, Corinne Haioun, Stephanie Guidez, Christophe Bonnet, Marc Andre, Liana Vereseza, Choquet Sylvain, Loic Ysebaert, Emmanuel Bachy, Fabrice Jardin, Franck Morschhauser, Vincent Ribrag

Blood (2023) 142 (Supplement 1): 853.

https://doi.org/10.1182/blood-2023-174607

Published: 2023

Journal Articles

Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

Blood (2023) 142 (Supplement 1): 1717.

https://doi.org/10.1182/blood-2023-188545

Published: 2023

Journal Articles

Distinct Circulating Genomic Features of Classical Hodgkin Lymphoma of Older Adults

Cédric Rossi, Jan Boegeholz, Stefan K. Alig, Andrea Garofalo, Mohammad Shahrokh Esfahani, Joseph Schroers-Martin, Mari Olsen, Xiaoman Kang, David M. Kurtz, Takeshi Sugio, Mark P. Hamilton, Marc Andre, Rene-Olivier Casasnovas, Luc Matthieu Fornecker, Maximilian Diehn, Herve Ghesquieres, Ash A. Alizadeh

Blood (2023) 142 (Supplement 1): 4369.

https://doi.org/10.1182/blood-2023-178257

Published: 2023

Journal Articles

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

Blood (2023) 142 (Supplement 1): 297.

https://doi.org/10.1182/blood-2023-185057

Published: 2023

Journal Articles

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Blood (2023) 142 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2023-188896

Published: 2023

Journal Articles

Real-World Effectiveness and Safety of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) in Belgium after 4 Years

Kirsten Saevels, Sylvia Snauwaert, Gaeten Vanstralen, Marc Andre, Fritz Offner, Ariane Maes, Marjolein Lahaye, Ann Janssens

Blood (2023) 142 (Supplement 1): 6550.

https://doi.org/10.1182/blood-2023-174762

Published: 2023

Journal Articles

Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods

Blood (2023) 142 (Supplement 1): 177.

https://doi.org/10.1182/blood-2023-186810

Published: 2023

Journal Articles

Blast Clearance after High Dose-Melphalan Conditioning for Allogeneic Stem Cell Transplantation in Relapsed and Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4911.

https://doi.org/10.1182/blood-2023-180723

Published: 2023

Journal Articles

Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2

Joshua Brody, Judit Mészáros Joergensen, David Belada, Regis T. Costello, Marek Trněný, Umberto Vitolo, David Lewis, Yasmin H. Karimi, Anna Maria Sureda Balari, Marc André, Björn E. Wahlin, Pieternella Lugtenburg, Faith Galderisi, Aqeel Abbas, Yaou Song, Malene Risum, Raul Cordoba

Blood (2023) 142 (Supplement 1): 3092.

https://doi.org/10.1182/blood-2023-180246

Published: 2023

NARROW

Post-Transplant Relapse in Patients Transplanted with Active Acute Myeloid Leukemia (AML) - Treatment Options and Outcomes at a Large AML Referral Center

Potent Activity of Duocarmyin- and Mmaf-Conjugated FLT3-Directed Antibody-Drug Conjugates Towards Acute Myeloid Leukemia Stem Cells in Vitro and In Vivo

Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling

Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial

Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa

Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma

COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy

The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

Induction and Maintenance Therapy in Elderly Patients with Mantle Cell Lymphoma: Double-Randomized MCL R2 Elderly Clinical Trial By the European Mantle Cell Lymphoma Network

R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

Results of the Phase II of Epirchop Study, Evaluating the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): A Lysa Study

Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

Distinct Circulating Genomic Features of Classical Hodgkin Lymphoma of Older Adults

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Real-World Effectiveness and Safety of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) in Belgium after 4 Years

Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods

Blast Clearance after High Dose-Melphalan Conditioning for Allogeneic Stem Cell Transplantation in Relapsed and Refractory Acute Myeloid Leukemia

Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only